Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study
In this real-world study, low- to medium-dose of telitacicept combined with conventional therapy showed rapid onset efficacy and safety for treating high-risk progressive IgA patients.
Authors
- Xiuhua Xu (ORCID: https://orcid.org/0000-0002-6280-902X)
- Leping Shao
- Xing Chen (ORCID: https://orcid.org/0000-0003-0670-2233)
- Jun Zhang (ORCID: https://orcid.org/0000-0003-1706-1611)
- Yinan Li (ORCID: https://orcid.org/0000-0001-8934-9361)
- Juan Pei (ORCID: https://orcid.org/0000-0003-4184-7120)
- Ruihong Huang (ORCID: https://orcid.org/0000-0002-4639-7766)
- Xuejuan Sun
- Lijing Yao
- Hengyuan Zhang
Institutions
- Fujian Medical University (CN)
- First Affiliated Hospital of Xiamen University (CN)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1186/s12882-025-04708-w
- Citations
- 2
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.86